1 Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
2 University of California San Francisco School of Pharmacy, San Francisco, California.
Ann Am Thorac Soc. 2018 Feb;15(2):192-199. doi: 10.1513/AnnalsATS.201606-492OC.
Human immunodeficiency virus (HIV) infection is associated with pulmonary disease and worse lung function, but the relationship of lung function with survival in HIV is unknown.
To determine whether lung function is associated with all-cause mortality in HIV-infected individuals.
HIV-infected participants from cohorts in three locations underwent pre- and post-bronchodilator spirometry and determination of single-breath diffusing capacity of the lung for carbon monoxide (Dl) in 2008-2009, computed tomographic (CT) scanning of the chest for quantitative emphysema and airway measures, and echocardiography for estimated left ventricular systolic and diastolic function and tricuspid regurgitant velocity. Bivariate analysis and multivariable Cox proportional hazards models were used to determine whether decreased lung function was independently associated with increased all-cause mortality. Models were adjusted for covariates including age, sex, body mass index, smoking status, self-reported hepatitis C status, HIV viral levels, CD4 T-cell counts, hemoglobin, antiretroviral therapy, and illicit drug use.
Overall, 396 HIV-infected participants underwent pulmonary function testing. Thirty-two participants (8%) died during a median follow-up period of 69 months. A post-bronchodilator FEV-to-FVC ratio less than 0.7 (hazard ratio [HR], 2.47; 95% confidence interval [CI], 1.10-5.58) and a Dl less than 60% (HR, 2.28; 95% CI, 1.08-4.82) were independently associated with worse mortality. Also, hepatitis C (HR, 2.68; 95% CI, 1.22-5.89) and baseline plasma HIV RNA level (HR per ln RNA copies/ml, 1.50; 95% CI, 1.22-1.86) were associated with mortality in HIV-infected participants. The only CT or echocardiographic measure associated with greater mortality in univariate analysis was greater wall thickness of medium-sized airways (HR for wall area percent, 1.08; 95% CI, 1.00-1.18; P = 0.051), but none of the CT or echocardiogram measures were associated with mortality in multivariable analysis.
Airflow obstruction and impaired diffusing capacity appear to be associated with all-cause mortality in HIV-infected persons over an average of 6 years of follow-up. These data highlight the importance of lung dysfunction in HIV-infected persons and should be confirmed in larger cohorts and with extended follow-up periods. Clinical trial registered with www.clinicaltrials.gov (NCT00869544, NCT01326572).
人类免疫缺陷病毒(HIV)感染与肺部疾病和更差的肺功能有关,但 HIV 患者的肺功能与生存率的关系尚不清楚。
确定肺功能是否与 HIV 感染者的全因死亡率相关。
2008-2009 年,来自三个地点队列的 HIV 感染者参与者接受了支气管扩张剂前和后肺量测定以及一氧化碳(CO)单肺弥散量(Dl)测定、胸部计算机断层扫描(CT)定量肺气肿和气道测量以及超声心动图用于评估左心室收缩和舒张功能以及三尖瓣反流速度。使用双变量分析和多变量 Cox 比例风险模型来确定肺功能下降是否与全因死亡率增加独立相关。模型调整了协变量,包括年龄、性别、体重指数、吸烟状况、自我报告的丙型肝炎状态、HIV 病毒载量、CD4 T 细胞计数、血红蛋白、抗逆转录病毒治疗和非法药物使用。
总体而言,396 名 HIV 感染者接受了肺功能检查。在中位随访 69 个月期间,有 32 名参与者(8%)死亡。支气管扩张剂后 FEV/FVC 比值<0.7(风险比[HR],2.47;95%置信区间[CI],1.10-5.58)和 Dl<60%(HR,2.28;95%CI,1.08-4.82)与死亡率增加独立相关。此外,丙型肝炎(HR,2.68;95%CI,1.22-5.89)和基线血浆 HIV RNA 水平(每 ln RNA 拷贝/ml 的 HR,1.50;95%CI,1.22-1.86)与 HIV 感染者的死亡率相关。在单变量分析中唯一与更高死亡率相关的 CT 或超声心动图测量值是中等气道壁面积百分比的增加(壁面积百分比 HR,1.08;95%CI,1.00-1.18;P=0.051),但在多变量分析中没有一项 CT 或超声心动图测量值与死亡率相关。
在平均 6 年的随访中,气流阻塞和弥散能力受损似乎与 HIV 感染者的全因死亡率相关。这些数据突出了肺功能障碍在 HIV 感染者中的重要性,应该在更大的队列和更长的随访期内得到证实。临床试验在 www.clinicaltrials.gov 注册(NCT00869544、NCT01326572)。